The potential benefits of medicinal Cannabis for people living with cancer include antiemetic effects, appetite stimulation, pain relief, and improved sleep. Although few relevant surveys of practice patterns exist, it appears that physicians caring for cancer patients in the United States who recommend medicinal Cannabis do so predominantly for symptom management. A growing number of pediatric patients are seeking symptom relief with Cannabis or cannabinoid treatment, although studies are limited. The American Academy of Pediatrics has not endorsed Cannabis and cannabinoid use because of concerns about brain development.
The arguments for hemp's advantages are mostly long-standing (aside from ongoing discoveries about cannabinoids, new applications in nanotechnology and industrial oils, and so on). But our current opportunities to advance hemp's status as a crop — as well as a transformed cultural climate for cannabis generally — certainly qualify as 'groundbreaking' conditions.
Industrial hemp is marketed a fiber, as a seed, or as a dual-purpose crop. Although detailed market information for hemp ins not readily available, estimates from Vote Hemp show that the total retail value of hemp products in the U.S. in 2017 was $820 million. This includes food and body products, clothing, auto parts, building materials, and other products.
On the federal level, several bills currently before Congress seek to change the way the government treats CBD. One such bill, the Compassionate Access Act, would exclude CBD from the classification of “marijuana” and remove both from the DEA’s list of Schedule I controlled substances. Rescheduling CBD in such a way would make research and cultivation of CBD much easier.
In the end, companies like HempMedsPx are asking consumers simply to trust them. CBD oils are never subjected to systematic testing by any U.S. regulatory body. The FDA regulates all pharmaceutical labs in the country. But cannabis labs like the ones that HempMedsPx and others use are not, because cannabis is not federally recognized as a legal drug.
Dr. Ethan Russo, medical director at Phytecs, a biotechnology company spearheading research into plant- based medicines and the endocannabinoid system, took issue with Titus’s claim, however. “Bioaccumulators can recruit heavy metals from the soil,” Russo said, “but breaking them down would be alchemy.” Government regulation of the pharmaceutical industry is designed to protect consumers from unfounded scientific claims.